ChemInform Abstract: Synthesis, Pharmacology and Therapeutic Potential of 10- Methoxypyrazino(1,2-a)indoles, Partial Agonists at the 5HT2C Receptor.

ChemInform ◽  
2010 ◽  
Vol 28 (33) ◽  
pp. no-no
Author(s):  
M. BOES ◽  
F. JENCK ◽  
J. R. MARTIN ◽  
J. L. MOREAU ◽  
V. MUTEL ◽  
...  
Keyword(s):  
Therapeutic Potential ◽  
Partial Agonists ◽  
5Ht2c Receptor

Therapeutic potential of the 5HT2C receptor agonist Ro 60-0175 in panic, depression and OCD

1997 ◽  
Vol 42 (1) ◽  
pp. 30S ◽  
Author(s):  
F. Jenck ◽  
M. Boes ◽  
J.R. Martin ◽  
A. Sleight ◽  
J.-L. Moreau
Keyword(s):  
Receptor Agonist ◽  
Therapeutic Potential ◽  
5Ht2c Receptor

Dopamine D 2 Partial Agonists – Discovery, Evolution, and Therapeutic Potential

2019 ◽  
pp. 83-130
Author(s):  
Marlene Jacobson ◽  
Wayne Childers ◽  
Magid Abou‐Gharbia
Keyword(s):  
Therapeutic Potential ◽  
Partial Agonists

scholarly journals Development and application of high-throughput screens for the discovery of compounds that disrupt ErbB4 signaling: Candidate cancer therapeutics

PLoS ONE ◽  
2020 ◽  
Vol 15 (12) ◽  
pp. e0243901
Author(s):  
Richard L. Cullum ◽  
Lauren M. Lucas ◽  
Jared I. Senfeld ◽  
John T. Piazza ◽  
Logan T. Neel ◽  
...  
Keyword(s):  
Cell Proliferation ◽  
Drug Discovery ◽  
Therapeutic Potential ◽  
Partial Agonist ◽  
Survival Rates ◽  
Cancer Therapeutics ◽  
The Cancer Genome Atlas ◽  
Data Set ◽  
Partial Agonists ◽  
Dependent Cell

Whereas recent clinical studies report metastatic melanoma survival rates high as 30–50%, many tumors remain nonresponsive or become resistant to current therapeutic strategies. Analyses of The Cancer Genome Atlas (TCGA) skin cutaneous melanoma (SKCM) data set suggests that a significant fraction of melanomas potentially harbor gain-of-function mutations in the gene that encodes for the ErbB4 receptor tyrosine kinase. In this work, a drug discovery strategy was developed that is based on the observation that the Q43L mutant of the naturally occurring ErbB4 agonist Neuregulin-2beta (NRG2β) functions as a partial agonist at ErbB4. NRG2β/Q43L stimulates tyrosine phosphorylation, fails to stimulate ErbB4-dependent cell proliferation, and inhibits agonist-induced ErbB4-dependent cell proliferation. Compounds that exhibit these characteristics likely function as ErbB4 partial agonists, and as such hold promise as therapies for ErbB4-dependent melanomas. Consequently, three highly sensitive and reproducible (Z’ > 0.5) screening assays were developed and deployed for the identification of small-molecule ErbB4 partial agonists. Six compounds were identified that stimulate ErbB4 phosphorylation, fail to stimulate ErbB4-dependent cell proliferation, and appear to selectively inhibit ErbB4-dependent cell proliferation. Whereas further characterization is needed to evaluate the full therapeutic potential of these molecules, this drug discovery platform establishes reliable and scalable approaches for the discovery of ErbB4 inhibitors.

Medicinal Chemistry and Therapeutic Potential of Agonists, Antagonists and Allosteric Modulators of A1 Adenosine Receptor: Current Status and Perspectives

2019 ◽  
Vol 25 (25) ◽  
pp. 2697-2715 ◽  
Author(s):  
Pran Kishore Deb ◽  
Satyendra Deka ◽  
Pobitra Borah ◽  
Sara N. Abed ◽  
Karl-Norbert Klotz
Keyword(s):  
Neuropathic Pain ◽  
Side Effects ◽  
Medicinal Chemistry ◽  
Therapeutic Potential ◽  
The Body ◽  
Current Status ◽  
Target Tissue ◽  
Allosteric Modulators ◽  
Partial Agonists ◽  
Wide Range

Adenosine is a purine nucleoside, responsible for the regulation of a wide range of physiological and pathophysiological conditions by binding with four G-protein-coupled receptors (GPCRs), namely A1, A2A, A2B and A3 adenosine receptors (ARs). In particular, A1 AR is ubiquitously present, mediating a variety of physiological processes throughout the body, thus represents a promising drug target for the management of various pathological conditions. Agonists of A1 AR are found to be useful for the treatment of atrial arrhythmia, angina, type-2 diabetes, glaucoma, neuropathic pain, epilepsy, depression and Huntington’s disease, whereas antagonists are being investigated for the treatment of diuresis, congestive heart failure, asthma, COPD, anxiety and dementia. However, treatment with full A1 AR agonists has been associated with numerous challenges like cardiovascular side effects, off-target activation as well as desensitization of A1 AR leading to tachyphylaxis. In this regard, partial agonists of A1 AR have been found to be beneficial in enhancing insulin sensitivity and subsequently reducing blood glucose level, while avoiding severe CVS side effects and tachyphylaxis. Allosteric enhancer of A1 AR is found to be potent for the treatment of neuropathic pain, culminating the side effects related to off-target tissue activation of A1 AR. This review provides an overview of the medicinal chemistry and therapeutic potential of various agonists/partial agonists, antagonists and allosteric modulators of A1 AR, with a particular emphasis on their current status and future perspectives in clinical settings.

Sign in / Sign up

Export Citation Format

Share Document